Trump unveils phased tariffs on generic drugs to boost US production

Key Points:

• President Donald Trump announced that imported generic drugs will remain tariff-free until August 1, 2026, followed by a phased tariff increase to 100% for one year and then 200%, aiming to encourage pharmaceutical manufacturing in the U.S.
• The phased tariff approach is intended to give drug companies time to relocate production domestically, with the goal of reshoring generic pharmaceutical manufacturing and reducing U.S. dependence on foreign suppliers.
• Trump's administration will maintain existing policies on patented, branded, and innovative drugs, while emphasizing a surge in domestic pharmaceutical facility investments.
• The Association for Accessible Medicines expressed cautious support for the policy but highlighted ongoing structural challenges in purchasing and reimbursement that affect domestic manufacturing growth.
• Generic drugs constitute over 90% of U.S. prescriptions and rely heavily on global supply chains, making supply chain resilience a key concern amid the proposed tariff changes.